A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Trial Details

NCT ID

NCT06841354

Phase

PHASE3

Sponsor

Merck Sharp & Dohme LLC

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Sacituzumab tirumotecan
Pembrolizumab
Rescue Medication
Paclitaxel
Nab-paclitaxel
Gemcitabine

Locations (sample)

Mobile, Alabama, United States|30.69436,-88.04305
Chandler, Arizona, United States|33.30616,-111.84125
Duarte, California, United States|34.13945,-117.97729
Irvine, California, United States|33.66946,-117.82311
Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

The main inclusion criteria include but are not limited to the following:
Has locally recurrent unresectable or metastatic TNBC that cannot be treated with curative intent
Has not received systemic treatment for locally recurrent unresectable or metastatic breast cancer
Participants previously treated for early-stage breast cancer must have completed all prior therapy for early-stage breast cancer with curative int…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →